|Bid||296.00 x 900|
|Ask||301.66 x 800|
|Day's Range||297.56 - 301.99|
|52 Week Range||221.49 - 372.61|
|Beta (3Y Monthly)||1.38|
|PE Ratio (TTM)||54.15|
|Earnings Date||Apr 22, 2019 - Apr 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||339.93|
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Investors pursuing a solid, dependable stock investment can often beRead More...
Where Druckenmiller Suggests Investing amid Market Fluctuation(Continued from Prior Part)Druckenmiller’s top buysIn this article, we’ll discuss Stanley Druckenmiller’s top buys in the fourth quarter. Druckenmiller seemed to be positive on
In the daily bar chart of ILMN, below, we can see that buyers have decided to show up around $270 as that level has held in December and again in late January. The daily On-Balance-Volume (OBV) line has been in a decline from early October but an upturn in February could be the end of that decline. In this weekly bar chart of ILMN, below, we can see that prices are below the cresting 40-week moving average line.
Illumina Inc engages in life science tools and machines for analyzing genetic material. Illumina Inc had annual average EBITDA growth of 23.00% over the past ten years. GuruFocus rated Illumina Inc the business predictability rank of 5-star.
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
Governments and physicians around the globe struggle to deliver high quality healthcare at a reasonable price. But fresh medical technology innovators are coming, and there's one in particular worth looking ...
This exciting area of cancer research could turn into a huge industry. How can investors potentially profit?
Illumina Inc NASDAQ/NGS:ILMNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ILMN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ILMN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ILMN totaled $15.95 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Illumina, Inc. (ILMN) announced today that Sue Siegel has joined the company’s Board of Directors effective February 5, 2019. Ms. Siegel is Chief Innovation Officer at General Electric (GE) and CEO of GE Ventures. Ms. Siegel has more than 30 years of corporate, entrepreneurial and venture capital experience.
The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN ), Novartis AG (NYSE: NVS ) and Illumina, Inc. (NASDAQ: ILMN ) reporting either disappointing results or ...
Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. On 30 December 2018, Illumina, Inc. (NASDAQ:ILMN) released Read More...
fell 5.3% to $270.27 Wednesday after the genetic testing tools company missed Wall Street's fourth-quarter earnings expectations. Leerink Partners Puneet Souda reiterated his outperform rating for Illumina and lowered his price target for Illumina to $365 from $380 to reflect its lowered growth guide. UBS analyst Daniel Brennan reiterated his buy rating and lowered his price target to $350 from $370 following the company's quarterly report.
Illumina, Inc. (NASDAQ: ILMN ) announced 2019 revenue growth guidance of 13-14 percent, and much of this revenue growth is expected to be in the back half of the year. Yet the company's first-quarter guidance ...